A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2021

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions

Atopic Healthy SubjectsAdult Subjects with Mild Allergic Diseases

Interventions

DRUG

YH35324

Subcutaneous injection of YH35324

DRUG

Placebo

Subcutaneous injection of None of active ingredient

DRUG

Omalizumab

Subcutaneous injection of Omalizumab

Trial Locations (4)

Seoul National University Bundang Hospital, Gumi

Ajou University Hospital, Suwon

Asan Medical Center, Pungnap-tong

Severance Hospital, Yonsei University Health System, Sinchon-dong

All Listed Sponsors

lead

Yuhan Corporation

INDUSTRY

NCT05061524 - A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects with Mild Allergic Diseases | Biotech Hunter | Biotech Hunter